Teva’s UK subsidiary has joined forces with techbio company Closed Loop Medicine to use its software as a medical device (SaMD) technology platform in the development of n
For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulat
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva
Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disord
The jury in a California court has sided with Gilead Sciences and Teva in a lawsuit that accused the drugmakers of conspiring to delay the launch of generic versions of th
After years of legal horse-trading, Teva looks like it has finally finalised a settlement that should allow it to put litigation over its role in fuelling the US opioid ep
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh